Tenaya Therapeutics (TNYA) EBIT (2020 - 2026)

Tenaya Therapeutics' EBIT history runs 7 years deep, the most recent figure standing at -$20.1 million for Q1 2026.

• In Q1 2026, EBIT rose 27.14% year-over-year to -$20.1 million; the TTM figure through Mar 2026 stood at -$85.9 million (up 21.75% YoY), while the FY2025 annual figure was -$93.3 million, up 19.51% from the prior year.
• EBIT was -$20.1 million for Q1 2026 at Tenaya Therapeutics, up from -$20.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$20.1 million in Q1 2026 to a low of -$35.1 million in Q2 2023.
• Historically, EBIT has averaged -$28.6 million across 5 years, with a median of -$30.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: EBIT slumped 137.73% in 2022, then rose 27.14% in 2026.
• A 5-year view of EBIT shows it stood at -$34.6 million in 2022, then grew by 8.98% to -$31.4 million in 2023, then grew by 21.61% to -$24.7 million in 2024, then rose by 15.73% to -$20.8 million in 2025, then climbed by 3.42% to -$20.1 million in 2026.
• The last three EBIT figures came in at -$20.1 million (Q1 2026), -$20.8 million (Q4 2025), and -$20.9 million (Q3 2025), per Business Quant data.